medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2013, Number 07-08

<< Back Next >>

Medicina & Laboratorio 2013; 19 (07-08)

Diabetes insipidus: overview and diagnosis in pediatric patients

Velásquez UJC, Campuzano MG, Alfaro VJM

Language: Spanish
References: 82
Page: 353-380
PDF size: 1218.33 Kb.


ABSTRACT

Diabetes insipidus is a disease characterized by partial or total inability to concentrate urine due to a vasopressin secretion deficiency (central diabetes insipidus), a resistance to its action (nephrogenic diabetes insipidus) or an excessive consumption of water (primary polydipsia). The main signs and symptoms of the disease are polydipsia, polyuria, and nocturia; central diabetes insipidus has an insidious onset, whereas nephrogenic diabetes insipidus has a gradual onset. Because of the advances in clinical laboratory, imaging techniques and molecular biology, the etiologic diagnosis of diabetes insipidus has improved, from 50% of patients with idiopathic diabetes insipidus to 10%-20% of patients; therefore, it has been achieved more timely treatments, resulting in reduction of the risk of sequela. Accordingly, it is pivotal to rule out secondary causes of diabetes insipidus, such as drug consumption or metabolic disorders in patents with nephrogenic diabetes insipidus, and brain tumors, encephalic trauma, infiltrative diseases, autoimmune disorders or central nervous system infections in case of patients suffering of central diabetes insipidus. Regarding treatment, it is recommended the use of desmopressin, an analogue of vasopressin, for the treatment of central diabetes insipidus, whereas water consumption, decrease of salt consumption and treatment with diuretic and non-steroidal antiinflammatory drugs are recommended for treatment of patients with nephrogenic diabetes insipidus.


REFERENCES

  1. Di Iorgi N, Napoli F, Allegri AE, Olivieri I, Bertelli E, Gallizia A, et al. Diabetes insipidus--diagnosis and management. Horm Res Paediatr 2012; 77: 69-84.

  2. Argente-Oliver J. Diabetes insípida. Madrid: Editorial Justim S.L.; 2009.

  3. Srivatsa A, Majzoub JA. Disorders of water homeostasis. In: Lifshitz F, ed. Pediatric Endocrinology. Vol. 2 (ed 5th). New York: Informa Healthcare USA Inc; 2007.

  4. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003; 17: 471- 503.

  5. Muglia LJ, Majzoub JA. Disorders of the posterior pituitary. In: Sperling MA, ed. Pediatric Endocrinology (ed 2nd). Philadelphia: Saunders 2002.

  6. Robinson AG, Verbalis JG. Posterior pituitary gland. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology (ed 10). Philadelphia: Saunders; 2002.

  7. Robinson A, Verbalis JG. Posterior pituitary. In: Melmed S, Polonski KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology (ed 11). Philadephia: Saunders Elsevier; 2008.

  8. DeBold CR, Sheldon WR, DeCherney GS, Jackson RV, Alexander AN, Vale W, et al. Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. J Clin Invest 1984; 73: 533-538.

  9. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 2004; 101: 10464-10469.

  10. Barat C, Simpson L, Breslow E. Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 2004; 43: 8191-8203.

  11. Castaño L, Calvo B, Vela A. Patología del metabolismo del agua asociado a enfermedad hipofisaria. Rev Esp Endocrinol Pediatr 2010; 1: 48-55.

  12. George CP, Messerli FH, Genest J, Nowaczynski W, Boucher R, Kuchel Orofo-Oftega M. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metab 1975; 41: 332-338.

  13. Thrasher TN. Baroreceptor regulation of vasopressin and renin secretion: low-pressure versus high-pressure receptors. Front Neuroendocrinol 1994; 15: 157-196.

  14. Llorens-Cortes C, Moos F. Opposite potentiality of hypothalamic coexpressed neuropeptides, apelin and vasopressin in maintaining body-fluid homeostasis. Prog Brain Res 2008; 170: 559-570.

  15. Kucharczyk J, Mogenson GJ. Separate lateral hypothalamic pathways for extracellular and intracellular thirst. Am J Physiol 1975; 228: 295-301.

  16. Ranadive SA, Rosenthal SM. Pediatric disorders of water balance. Pediatr Clin North Am 2011; 58: 1271- 1280, xi-xii.

  17. Salata RA, Verbalis JG, Robinson AG. Cold water stimulation of oropharyngeal receptors in man inhibits release of vasopressin. J Clin Endocrinol Metab 1987; 65: 561-567.

  18. Thompson CJ, Burd JM, Baylis PH. Acute suppression of plasma vasopressin and thirst after drinking in hypernatremic humans. Am J Physiol 1987; 252: R1138- 1142.

  19. Maybauer MO, Maybauer DM, Enkhbaatar P, Traber DL. Physiology of the vasopressin receptors. Best Pract Res Clin Anaesthesiol 2008; 22: 253-263.

  20. Phillips PA, Abrahams JM, Kelly JM, Mooser V, Trinder D, Johnston CI. Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands. Endocrinology 1990; 126: 1478-1484.

  21. Robertson GL. The regulation of vasopressin function in health and disease. Recent Prog Horm Res 1976; 33: 333-385.

  22. Bealer SL, Crofton JT, Share L. Hypothalamic knife cuts alter fluid regulation, vasopressin secretion, and natriuresis during water deprivation. Neuroendocrinology 1983; 36: 364-370.

  23. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11: 406-410.

  24. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002; 82: 205-244.

  25. Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973; 52: 3212-3219.

  26. Robertson GL, Athar S. The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 1976; 42: 613-620.

  27. Bellastella A, Bizzarro A, Colella C, Bellastella G, Sinisi AA, De Bellis A. Subclinical diabetes insipidus. Best Pract Res Clin Endocrinol Metab 2012; 26: 471-483.

  28. Loureiro C, Martínez A, Fernández R, Lizama M, Cattani A, García H. Diabetes insípida en pediatría. Serie clínica y revisión de la literatura. Rev Chil Pediatr 2009; 80: 245-255.

  29. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16: 2836-2846.

  30. Hensen J, Buchfelder M. The posterior pituitary and its disease. In: Pinchera A, Fischer J, Schoemaker J, Groop L, Bertagna X, eds. Endocrinology and metabolism. New York: McGraw-Hill; 2001.

  31. Ball S. Diabetes insipidus. Pituitary 2005; 33: 18-19.

  32. Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Zecca S, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000; 343: 998-1007.

  33. Fenske W, Allolio B. Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab 2012; 97: 3426-3437.

  34. Baylis PH, Cheetham T. Diabetes insipidus. Arch Dis Child 1998; 79: 84-89.

  35. Davies JH, Penney M, Abbes AP, Engel H, Gregory JW. Clinical features, diagnosis and molecular studies of familial central diabetes insipidus. Horm Res 2005; 64: 231-237.

  36. Bullmann C, Kotzka J, Grimm T, Heppner C, Jockenhovel F, Krone W, et al. Identification of a novel mutation in the arginine vasopressin-neurophysin II gene in familial central diabetes insipidus. Exp Clin Endocrinol Diabetes 2002; 110: 134-137.

  37. Santiprabhob J, Browning J, Repaske D. A missense mutation encoding Cys73Phe in neurophysin II is associated with autosomal dominant neurohypophyseal diabetes insipidus. Mol Genet Metab 2002; 77: 112-118.

  38. Lee YW, Lee KW, Ryu JW, Mok JO, Ki CS, Park HK, et al. Mutation of Glu78 of the AVP-NPII gene impairs neurophysin as a carrier protein for arginine vasopressin in a family with neurohypophyseal diabetes insipidus. Ann Clin Lab Sci 2008; 38: 12-14.

  39. Ghirardello S, Garre ML, Rossi A, Maghnie M. The diagnosis of children with central diabetes insipidus. J Pediatr Endocrinol Metab 2007; 20: 359-375.

  40. Repaske DR, Medlej R, Gultekin EK, Krishnamani MR, Halaby G, Findling JW, et al. Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab 1997; 82: 51-56.

  41. Domenech E, Gomez-Zaera M, Nunes V. Wolfram/ DIDMOAD syndrome, a heterogenic and molecularly complex neurodegenerative disease. Pediatr Endocrinol Rev 2006; 3: 249-257.

  42. Kelberman D, Dattani MT. Genetics of septo-optic dysplasia. Pituitary 2007; 10: 393-407.

  43. Masera N, Grant DB, Stanhope R, Preece MA. Diabetes insipidus with impaired osmotic regulation in septo-optic dysplasia and agenesis of the corpus callosum. Arch Dis Child 1994; 70: 51-53.

  44. Charmandari E, Brook CG. 20 years of experience in idiopathic central diabetes insipidus. Lancet 1999; 353: 2212-2213.

  45. Alharfi IM, Stewart TC, Foster J, Morrison GC, Fraser DD. Central diabetes insipidus in pediatric severe traumatic brain injury. Pediatr Crit Care Med 2013; 14: 203-209.

  46. Nemergut EC, Zuo Z, Jane JA, Jr., Laws ER, Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg 2005; 103: 448-454.

  47. Kanagaki M, Miki Y, Takahashi JA, Shibamoto Y, Takahashi T, Ueba T, et al. MRI and CT findings of neurohypophyseal germinoma. Eur J Radiol 2004; 49: 204-211.

  48. Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, et al. Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab 1997; 82: 1362-1367.

  49. Christensen JH, Rittig S. Familial neurohypophyseal diabetes insipidus--an update. Semin Nephrol 2006; 26: 209-223.

  50. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001; 30: 671-694, vii.

  51. Ghirardello S, Hopper N, Albanese A, Maghnie M. Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab 2006; 19 Suppl 1: 413- 421.

  52. Grois N, Potschger U, Prosch H, Minkov M, Arico M, Braier J, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46: 228-233.

  53. De Bellis A, Sinisi AA, Pane E, Dello Iacovo A, Bellastella G, Di Scala G, et al. Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells. J Clin Endocrinol Metab 2012; 97: 3684-3690.

  54. Pivonello R, De Bellis A, Faggiano A, Di Salle F, Petretta M, Di Somma C, et al. Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. J Clin Endocrinol Metab 2003; 88: 1629- 1636.

  55. Maghnie M, Genovese E, Sommaruga MG, Arico M, Locatelli D, Arbustini E, et al. Evolution of childhood central diabetes insipidus into panhypopituitarism with a large hypothalamic mass: is ‘lymphocytic infundibuloneurohypophysitis’ in children a different entity? Eur J Endocrinol 1998; 139: 635-640.

  56. De Bellis A, Colao A, Di Salle F, Muccitelli VI, Iorio S, Perrino S, et al. A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. J Clin Endocrinol Metab 1999; 84: 3047-3051.

  57. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264: 92-95.

  58. Loonen AJ, Knoers NV, van Os CH, Deen PM. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28: 252-265.

  59. Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 2005; 45: 626-637.

  60. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 21: 449-456.

  61. Kortenoeven ML, Schweer H, Cox R, Wetzels JF, Deen PM. Lithium reduces aquaporin-2 transcription independent of prostaglandins. Am J Physiol Cell Physiol 2012; 302: C131-140.

  62. Wilting I, Baumgarten R, Movig KL, van Laarhoven J, Apperloo AJ, Nolen WA, et al. Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration. Eur J Pharmacol 2007; 566: 50-57.

  63. Ahmad IA, Al-Agha AE. Hypervitaminosis D causing nephrogenic diabetes insipidus in a 5-month-old infant. Saudi Med J 2013; 34: 187-189.

  64. Kim GH, Choi NW, Jung JY, Song JH, Lee CH, Kang CM, et al. Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2. Am J Physiol Renal Physiol 2008; 294: F702-709.

  65. Matoussi N, Aissa K, Fitouri Z, Hajji M, Makni S, Bellagha I, et al. [Central diabetes insipidus: diagnostic difficulties]. Ann Endocrinol (Paris) 2008; 69: 231- 239.

  66. Majzoub JA, Srivatsa A. Diabetes insipidus: clinical and basic aspects. Pediatr Endocrinol Rev 2006; 4 Suppl 1: 60-65.

  67. Mishra G, Chandrashekhar SR. Management of diabetes insipidus in children. Indian J Endocrinol Metab 2011; 15 Suppl 3: S180-187.

  68. Milles JJ, Spruce B, Baylis PH. A comparison of diagnostic methods to differentiate diabetes insipidus from primary polyuria: a review of 21 patients. Acta Endocrinol (Copenh) 1983; 104: 410-416.

  69. Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Muller B, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007; 92: 2640-2643.

  70. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: I129-138.

  71. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52: 2340-2352.

  72. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem 1999; 45: 98-103.

  73. Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 1995; 332: 1540-1545.

  74. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.

  75. Alter CA, Bilaniuk LT. Utility of magnetic resonance imaging in the evaluation of the child with central diabetes insipidus. J Pediatr Endocrinol Metab 2002; 15 Suppl 2: 681-687.

  76. Gudinchet F, Brunelle F, Barth MO, Taviere V, Brauner R, Rappaport R, et al. MR imaging of the posterior hypophysis in children. AJR Am J Roentgenol 1989; 153: 351-354.

  77. Alonso G, Bergada I, Heinrich JJ. [Magnetic resonance imaging in central diabetes insipidus in children and adolescents. findings at diagnosis and during follow-up]. An Esp Pediatr 2000; 53: 100-105.

  78. Shin JH, Lee HK, Choi CG, Suh DC, Kim CJ, Hong SK, et al. MR imaging of central diabetes insipidus: a pictorial essay. Korean J Radiol 2001; 2: 222-230.

  79. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967; 42: 790-806.

  80. Maghnie M, Genovese E, Lundin S, Bonetti F, Arico M. Iatrogenic [corrected] extrapontine myelinolysis in central diabetes insipidus: are cyclosporine and 1-desamino-8-D-arginine vasopressin harmful in association? J Clin Endocrinol Metab 1997; 82: 1749- 1751.

  81. Maghnie M, Genovese E, Bernasconi S, Binda S, Arico M. Persistent high MR signal of the posterior pituitary gland in central diabetes insipidus. AJNR Am J Neuroradiol 1997; 18: 1749-1752.

  82. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 2013; 34: 278-301.




2020     |     www.medigraphic.com